Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to tame dangerously high blood fats

NCT ID NCT07269210

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 7 times

Summary

This study tests an injectable drug called solbinsiran in 60 adults with severe hypertriglyceridemia (very high blood fats). Participants receive two shots of either the drug or a placebo. The goal is to see if solbinsiran safely lowers triglycerides and related fats better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Solbinsiran (also called LY3561774), an injectable drug
What this could lead to
If it works, this could lead to a new treatment option for people with dangerously high triglycerides, reducing their risk of pancreatitis and heart problems.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may not lower triglycerides enough or could have side effects not yet seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history * Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart) * Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive) Exclusion Criteria: * Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening * Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome * Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral vector-mediated, or other genetic modification techniques * Have a history of chronic alcohol abuse within 3 years prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe hypertriglyceridemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe hypertriglyceridemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    36 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AB Clinical Trials

    RECRUITING

    Las Vegas, Nevada, 89119, United States

  • ARC Biosystems

    RECRUITING

    Vancouver, V6Z 2H2, Canada

  • American Research Corporation at Texas Liver Institute

    RECRUITING

    San Antonio, Texas, 78215, United States

  • Ark Clinical Research

    RECRUITING

    Long Beach, California, 90815, United States

  • C.I.C. Mauricie inc.

    RECRUITING

    Trois-Rivières, G8T 7A1, Canada

  • CMR of Greater New Haven, LLC

    RECRUITING

    Hamden, Connecticut, 06517, United States

  • Cardiovascular Specialists of Willowbrook

    RECRUITING

    Houston, Texas, 77070, United States

  • Carilion Clinic

    RECRUITING

    Roanoke, Virginia, 24014, United States

  • Catalina Research Institute, LLC

    RECRUITING

    Montclair, California, 91763, United States

  • Clinical Research of Philadelphia

    RECRUITING

    Pennington, New Jersey, 08534, United States

  • Clinical Site Partners, LLC dba Flourish Research

    RECRUITING

    Winter Park, Florida, 32789, United States

  • Eastside Research Associates

    RECRUITING

    Redmond, Washington, 98052, United States

  • Ecogene-21

    RECRUITING

    Chicoutimi, G7H 7K9, Canada

  • Endeavor Clinical Trials

    RECRUITING

    San Antonio, Texas, 78240, United States

  • Flourish Research - Bowie

    RECRUITING

    Bowie, Maryland, 20715, United States

  • Great Lakes Clinical Trials - Ravenswood

    RECRUITING

    Chicago, Illinois, 60640, United States

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, 510000, China

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

  • Inpatient Research Clinic

    RECRUITING

    Miami Lakes, Florida, 33014, United States

  • Investigators Research Group

    RECRUITING

    Brownsburg, Indiana, 46112, United States

  • Medical Corporation Heishinkai OCROM Clinic

    COMPLETED

    Suita-shi, 565-0853, Japan

  • National Heart Institute

    COMPLETED

    Beverly Hills, California, 90211, United States

  • Northeast Research Institute - Downtown Office

    RECRUITING

    Jacksonville, Florida, 32204, United States

  • Novera Clinical Research

    RECRUITING

    Miami, Florida, 33135, United States

  • Onyx Clinical Research

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85014, United States

  • Peking University Third Hospital

    RECRUITING

    Beijing, 100091, China

  • Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital

    RECRUITING

    Covington, Kentucky, 41011, United States

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, 610072, China

  • Southern Endocrinology Associates

    RECRUITING

    Mesquite, Texas, 75149, United States

  • Stroobants Cardiovascular Center

    COMPLETED

    Lynchburg, Virginia, 24501, United States

  • Synexus Clinical Research US, Inc./Orange Grove Family Practice

    RECRUITING

    Tucson, Arizona, 85741, United States

  • TPMG (Tidewater Physicians Multispecialty Group) Clinical Research

    RECRUITING

    Newport News, Virginia, 23606, United States

  • Takai Internal Medicine Clinic

    ACTIVE_NOT_RECRUITING

    Kamakura-shi, 247-0056, Japan

  • The Affiliated Hospital of Xuzhou Medical College

    RECRUITING

    Xuzhou, 221006, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    RECRUITING

    Luoyang, 471003, China

  • The Institute of Medical Science, Asahi Life Foundation

    ACTIVE_NOT_RECRUITING

    Chūōku, 103-0002, Japan

  • UW Medicine Diabetes Institute

    RECRUITING

    Seattle, Washington, 98109, United States

  • University of Massachusetts Chan Medical School

    RECRUITING

    Worcester, Massachusetts, 01655, United States

  • Valley Clinical Trials, LLC dba Flourish Research

    RECRUITING

    Northridge, California, 91325, United States

  • Weill Cornell Medical College

    RECRUITING

    New York, New York, 10021, United States

  • Zhongshan Hospital,Fudan University

    RECRUITING

    Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.